Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

FDA stamp of approval | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

December 16th 2024

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

man resting hands on top of walking cane | Image Credit: sergign - stock.adobe.com
Study Finds Increased Impaired Mobility by Sex, Age in Atopic Dermatitis

June 30th 2024

E-cigarettes | Image Credit: lezinav - stock.adobe.com
Parental e-Cigarette Use May Increase Pediatric AD Risk

May 22nd 2024

Female patient with AD | Image Credit: Prostock-studio - stock.adobe.com
Study: Visible AD Impacts Romantic Relationships, Occupation, Sexual Health of French Female Patients

May 19th 2024

Patient scratching atopic dermatitis (AD) on hand | Image Credit: Ольга Тернавская - stock.adobe.com
Patients With AD Prioritize Itch Control in Treatment Preferences

May 14th 2024

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

Exploring Clinical, Diagnostic Features of Photoaggravated Atopic Dermatitis
August 2nd 2022

Exploring Clinical, Diagnostic Features of Photoaggravated Atopic Dermatitis

Matthew Gavidia
Substantially impaired quality of life was shown in patients with photoaggravated atopic dermatitis, with phototesting cited as an effective diagnostic approach in promoting personalized care.
Atopic dermatitis.
July 29th 2022

Overuse of Systemic Corticosteroids, Substantial Cost Burden for AD Seen in Germany

Matthew Gavidia
Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.
Elaine Siegfried, MD.
July 23rd 2022

Dr Elaine Siegfried Discusses Step Edits, Barriers to AD Treatment

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on step edits and other barriers limiting access to biologic, topical, and other medications for the treatment of atopic dermatitis (AD).
Child patient.
July 20th 2022

Examining the Impact of Atopic Dermatitis Severity on Families of Pediatric Patients

Matthew Gavidia
Increased atopic dermatitis severity in pediatric patients was associated with a greater physical, emotional, social, and economic impact on families.
skin pain/itch.
July 11th 2022

Itch and Skin Pain in Patients With AD Linked With Significant QOL Burden

Matthew Gavidia
The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs.
patient speaking with doctor
July 6th 2022

Disease Severity, Time Managing Symptoms Contribute to High Disease Burden for Patients With AD

Lindsey Mulrooney
A majority of patients with moderate or severe atopic dermatitis (AD) reported moderate-to-high negative impacts on quality of life.
Elaine Siegfried, MD.
July 2nd 2022

Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.
group of diverse teenagers
June 30th 2022

Dupilumab Effective for Pediatric, Adolescent Patients With AD Regardless of Age, Sex, Race

Lindsey Mulrooney
Patients from this diverse cohort experienced improvements in atopic dermatitis (AD) clinical scores after a year or more of treatment with dupilumab.
Robert Sidbury.
June 25th 2022

Dr Robert Sidbury on Promoting Therapeutic Adherence in Pediatric Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, speaks on strategies that clinicians can employ to promote adherence of topical and oral medications in pediatric patients with atopic dermatitis.
child with a mask.
June 24th 2022

Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children

Matthew Gavidia
Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
Elaine Siegfried, MD.
June 16th 2022

Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months
June 9th 2022

FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months

AJMC Staff
The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
Patient and physician.
June 8th 2022

Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count

Matthew Gavidia
Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
puzzled brain.
June 7th 2022

Risk of Dementia Elevated in Patients With Atopic Dermatitis

Matthew Gavidia
A study of UK electronic health record data indicated patients with atopic dermatitis (AD) showed an increased risk of dementia compared with the general population.
Robert Sidbury, MD, MPH.
June 3rd 2022

Dr Robert Sidbury Reviews Novel Topical, Systemic Therapies for Pediatric Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.
Food.
May 31st 2022

Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases

Matthew Gavidia
Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
doctor inspecting skin.
May 26th 2022

Greater Atopic Dermatitis Severity May Increase Risk of Certain Cancers

Matthew Gavidia
Pediatric and adult patients reporting more severe disease courses of atopic dermatitis had a greater risk of select cancers, particularly lymphoma.
Elaine Siegfried, MD
May 19th 2022

Dr Elaine Siegfried Discusses Skin Color, Socioeconomic Implications of Atopic Dermatitis Management

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
Atopic dermatitis.
May 17th 2022

Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis

Matthew Gavidia
Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Robert Sidbury, MD, MPH.
May 13th 2022

Dr Robert Sidbury Discusses Strategies to Promote Earlier Uptake of Novel Atopic Dermatitis Therapies

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Stethoscope next to a teddy bear and blocks.
May 10th 2022

Study Shows Caregivers Prefer Dermatology Specialists Over PCPs for Pediatric Atopic Dermatitis

Matthew Gavidia
Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.
Elaine Siegfried, MD.
May 6th 2022

Dr Elaine Siegfried on Safety Considerations for JAK Inhibitors in Pediatric Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on safety considerations for the use of Janus kinase (JAK) inhibitors in pediatric patients with atopic dermatitis.
Frustrated patient.
May 4th 2022

High Disability Burden of Atopic Dermatitis Linked With Socioeconomic Status

Matthew Gavidia
Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Robert Sidbury, MD, MPH.
April 28th 2022

Dr Robert Sidbury on Mental Health Implications of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on the mental health comorbidity risk linked with atopic dermatitis and how dermatologists can play a role in managing behavioral care needs of at-risk patients.
cream.
April 25th 2022

Improved Severity of Atopic Dermatitis Achieved With Adjuvant Dupilumab, Tacrolimus

Matthew Gavidia
More patients with atopic dermatitis achieved mild disease severity by 1 month of treatment with adjuvant dupilumab and tacrolimus vs dupilumab alone.
Elaine Siegfried, MD.
April 20th 2022

Dr Elaine Siegfried on Considerations for Systemic Therapy Use in Pediatric Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.
Physician examining skin of patient.
April 18th 2022

Investigating Lifestyle Behaviors Associated With Moderate to Severe Atopic Dermatitis

Matthew Gavidia
Several modifiable lifestyle factors were associated with moderate to severe atopic dermatitis in a patient cohort from the Netherlands, including smoking, alcohol consumption, and stress.
Elaine Siegfried, MD.
April 14th 2022

Dr Elaine Siegfried Overviews Pathology, Targeted Therapy in Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.
Doctor talking to a patient
April 11th 2022

Dupilumab Creates Rapid, Sustained Responses in Asthma, CRSwNP, and AD

Laura Joszt, MA
Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.
Robert Sidbury, MD, MPH.
April 8th 2022

Dr Robert Sidbury Discusses Impact of New AAD Guidelines on Atopic Dermatitis Treatment

Matthew Gavidia
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.
<12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo